Autism Patients Show Progress Following Stem Cell Therapy in Germany

Share Article

The XCell-Center has released interim results from 10 autism patients treated with autologous bone marrow stem cells. Overall, more than 70% improved following treatment.

The XCell-Center has released interim results from 10 autism patients treated with autologous bone marrow stem cells. Overall, more than 70% improved following treatment.

Patients reported improvements in cognition, behavior, language, socialization, coordination, motor skills and awareness. These results support the premise that patients with Autism can be treated safely and effectively with autologous stem cell therapy.

"My son's behavior has improved; playing for an hour at a time, running, climbing, and exploring the playground as a normal, healthy child would," commented the mother of a 6 year-old boy who was treated at the XCell-Center in May 2009.

Better behavior was reported by every patient who experienced improvements following treatment.

In a letter written February 2009, "A letter to President Obama", Judy DiCorcia, the mother of 10 year-old Lauren, who was treated at the XCell-Center in January, described the strides her daughter made following stem cell therapy and expressed her desire to see similar procedures available in the United States. "Both procedures were quick and not invasive at all. In the past 6 weeks we have seen significant improvements in our daughter's behaviors, focus, hyperactivity, and insomnia," wrote Mrs. DiCorcia. In June 2009, she stated, "Lauren is doing well. I would have to say that she 'plateaued' at about the 12-week mark. Her situation is stable and fortunately all positive effects have persisted. I wish the doctor could fly to the US and perform the therapy here!"

"Although these are only preliminary results based on a small number of patients, we find them extremely encouraging. We intend to release comprehensive results and statistics following a planned US clinical trial in 2010 or 2011. In the mean time, we will continue to treat autistic children privately in Dusseldorf and we expect results similar to those already observed," said Dr. Hans de Munter, the XCell-Center's Chief Scientific Officer.

The treatment begins by collecting a small amount bone marrow from the patient's hip via thin needle mini-puncture. The stem cells are separated from the bone marrow at the XCell-Center's EU certified cGMP laboratory, where they are counted and their vitality is confirmed. The last step consists of inserting a fine spinal needle between the patient's L4 and L5 vertebrae and injecting the stem cells into the cerebrospinal fluid which flows into the brain.

The cost for Autism treatment is 9,000 Euros.

About the XCell-Center
The XCell-Center operates treatment centers in Cologne and Dusseldorf, Germany. It is the first privately-owned clinic in Europe to specialize in regenerative medicine using autologous bone marrow stem cell therapy and operates in accordance with German law and European guidelines. Its specialized medical team of German physicians includes specialists in: neurosurgery, orthopedics, cardiology, radiology, anesthesiology and pharmacology.

The XCell-Center also treats Diabetes and its complications (Erectile Dysfunction and Peripheral Artery Disease), Stroke, Cerebral Palsy, Spinal Cord Injuries, Orthopedic diseases, Heart Disease and degenerative diseases such as Multiple Sclerosis, Parkinson's, Alzheimer's and several eye diseases.

For more information on Stem Cell Therapy:

XCell-Center Website:

XCell-Center GmbH
at the Institute for Regenerative Medicine
Am Heerdter Krankenhaus 2
40549 Dusseldorf, Germamy

Phone: 1-866-680-8202 (USA Toll-Free) (+49) 0221-802-5095 (Germany)

Fax: 1-713-583-9322 (USA)    (+49) 0221-2921-2550 (Germany)


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay Lenner
Visit website